CN1392148A - 5-benzyloxymethyl-1,4-dioxane-2-one and its preparing method and use - Google Patents
5-benzyloxymethyl-1,4-dioxane-2-one and its preparing method and use Download PDFInfo
- Publication number
- CN1392148A CN1392148A CN 02138741 CN02138741A CN1392148A CN 1392148 A CN1392148 A CN 1392148A CN 02138741 CN02138741 CN 02138741 CN 02138741 A CN02138741 A CN 02138741A CN 1392148 A CN1392148 A CN 1392148A
- Authority
- CN
- China
- Prior art keywords
- dioxane
- ketone
- benzyloxymethyl
- prepare
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SCEUEVMPCRJUCB-UHFFFAOYSA-N 5-(phenylmethoxymethyl)-1,4-dioxan-2-one Chemical compound C1OC(=O)COC1COCC1=CC=CC=C1 SCEUEVMPCRJUCB-UHFFFAOYSA-N 0.000 title abstract description 12
- 238000000034 method Methods 0.000 title description 4
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920001577 copolymer Polymers 0.000 claims abstract description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000012312 sodium hydride Substances 0.000 claims description 8
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000007306 functionalization reaction Methods 0.000 claims 2
- 229940088623 biologically active substance Drugs 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000000178 monomer Substances 0.000 abstract description 12
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 abstract description 11
- 239000000622 polydioxanone Substances 0.000 abstract description 11
- 229920000642 polymer Polymers 0.000 abstract description 11
- HIQHCIVHNZGOKR-UHFFFAOYSA-N 5-(hydroxymethyl)-1,4-dioxan-2-one Chemical compound OCC1COC(=O)CO1 HIQHCIVHNZGOKR-UHFFFAOYSA-N 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 7
- 230000004071 biological effect Effects 0.000 abstract description 6
- 229940073608 benzyl chloride Drugs 0.000 abstract description 5
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 abstract description 4
- 238000013270 controlled release Methods 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- -1 5-benzyloxy Methyl-1,4-dioxane-2-one Chemical compound 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VCKSNYNNVSOWEE-UHFFFAOYSA-N 1,3-dioxan-5-ol Chemical compound OC1COCOC1 VCKSNYNNVSOWEE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920001963 Synthetic biodegradable polymer Polymers 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000001955 polymer synthesis method Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
5-苄氧甲基-1,4-二氧六环-2-酮,其结构式为(见右式),本发明提供了5-苄氧甲基-1,4-二氧六环-2-酮的制备方法:以5-羟甲基-1,4-二氧六环-2-酮和苄氯为原料在氢化钠或氢氧化钠或金属钠存在下回流反应制得5-苄氧甲基-1,4-二氧六环-2-酮。所得化合物单体用于制备功能化生物可降解聚对二氧六环酮、生物可降解共聚物,可改善相应聚合物的物理、化学和生物学性能。作为中间体用于制备功能化环状对二氧六环酮以及聚对二氧六环酮、用于制备含药物或生物活性物质的环状中间体,从而制备高分子药物控释体系。
5-benzyloxymethyl-1,4-dioxane-2-one, its structural formula is (see the formula on the right), the present invention provides 5-benzyloxymethyl-1,4-dioxane-2 The preparation method of -ketone: take 5-hydroxymethyl-1,4-dioxane-2-one and benzyl chloride as raw materials to prepare 5-benzyloxy Methyl-1,4-dioxane-2-one. The obtained compound monomer is used to prepare functionalized biodegradable polydioxanone and biodegradable copolymers, which can improve the physical, chemical and biological properties of corresponding polymers. As an intermediate, it is used to prepare functionalized cyclic p-dioxanone and polydioxanone, and is used to prepare cyclic intermediates containing drugs or biologically active substances, so as to prepare polymer drug controlled release systems.
Description
技术领域technical field
本发明涉及5-苄氧甲基-1,4-二氧六环-2-酮及其制备方法和用途,属于有机化学领域。The invention relates to 5-benzyloxymethyl-1,4-dioxane-2-one and its preparation method and application, belonging to the field of organic chemistry.
背景技术Background technique
开环聚合是重要的高分子合成方法之一。常见的合成生物可降解高分子如聚酯、聚氨基酸、聚碳酸酯、聚磷酸酯和聚对二氧六环酮等,一般都通过开环聚合来制备。为了进一步发展生物可降解高分子,重要的途径之一就是设计和合成结构新颖的环状单体。Ring-opening polymerization is one of the important polymer synthesis methods. Common synthetic biodegradable polymers such as polyesters, polyamino acids, polycarbonates, polyphosphates, and polydioxanone are generally prepared by ring-opening polymerization. In order to further develop biodegradable polymers, one of the important approaches is to design and synthesize cyclic monomers with novel structures.
在生物降解性脂肪族聚酯材料中,聚对二氧六环酮(PDON)由于植入体内后既没有急性炎症,也没有毒副作用,而能够安全地用于体内。并且因为它的较低的玻璃化转变温度(-16℃)和较好的柔韧性,作为较好的生物医用材料被临床用作手术缝合线。但是由于PDON有大约55%的结晶性,在一定程度上影响它的亲水性,并使其降解时间为6个月,我们在其主链上引入侧链羟基以期提高它的亲水性,从而加快其降解速度。这一工作的重要意义在于:①可通过控制引入官能团的比例来改变聚合物的亲水/疏水性;②通过侧链官能团的引入可以改变聚合物的降解速率,并可通过控制引入官能团的比例来控制降解速率的大小;③可在侧链官能团上键合各种药物,形成药物控释体系。Among biodegradable aliphatic polyester materials, polydioxanone (PDON) can be safely used in vivo because it has neither acute inflammation nor toxic side effects after implantation. And because of its lower glass transition temperature (-16°C) and better flexibility, it is clinically used as a surgical suture as a better biomedical material. However, since PDON has about 55% crystallinity, which affects its hydrophilicity to a certain extent, and makes its degradation time 6 months, we introduce side chain hydroxyl groups on its main chain in order to improve its hydrophilicity. thereby accelerating its degradation rate. The significance of this work lies in: ① the hydrophilicity/hydrophobicity of the polymer can be changed by controlling the ratio of the introduced functional groups; ② the degradation rate of the polymer can be changed by the introduction of side chain functional groups, and the to control the degradation rate; ③ Various drugs can be bonded to the side chain functional groups to form a drug controlled release system.
发明内容Contents of the invention
本发明的目的是提供一种新的含功能基团的六员环对二氧六环酮单体:5-苄氧甲基-1,4-二氧六环-2-酮及其制备方法和用途,通过改变环状单体上的官能团,可改变相应聚合物的物理、化学和生物学性质,并可将药物通过官能团引入单体或聚合物,从而为进一步拓展生物可降解聚对二氧六环酮及其共聚物的应用领域奠定良好的基础。The object of the present invention is to provide a new six-membered ring-p-dioxanone monomer containing functional groups: 5-benzyloxymethyl-1,4-dioxan-2-one and its preparation method and applications, by changing the functional groups on the cyclic monomers, the physical, chemical and biological properties of the corresponding polymers can be changed, and drugs can be introduced into the monomers or polymers through the functional groups, thus further expanding the biodegradable poly The application fields of oxyhexanone and its copolymers have laid a good foundation.
为实现本发明的上述目的所采取的技术措施:The technical measures taken for realizing the above-mentioned purpose of the present invention:
5-苄氧甲基-1,4-二氧六环-2-酮,其结构式为: 5-benzyloxymethyl-1,4-dioxane-2-one, its structural formula is:
本发明提供了5-苄氧甲基-1,4-二氧六环-2-酮的制备方法:以5-羟甲基-1,4-二氧六环-2-酮和苄氯为原料在氢化钠或氢氧化钠或金属钠存在下回流反应制得5-苄氧甲基-1,4-二氧六环-2-酮。The invention provides a preparation method of 5-benzyloxymethyl-1,4-dioxane-2-one: using 5-hydroxymethyl-1,4-dioxane-2-one and benzyl chloride as The raw materials are refluxed in the presence of sodium hydride or sodium hydroxide or sodium metal to prepare 5-benzyloxymethyl-1,4-dioxane-2-one.
上述5-羟甲基-1,4-二氧六环-2-酮可通过现有技术得到;也可由下法制得:将5-羟基-1,3-苄叉甘油与溴乙酸乙酯在金属钠或氢化钠存在下45~65℃反应,再经碱性条件和酸性条件两次水解后减压蒸馏制得5-羟甲基-1,4-二氧六环-2-酮,再以5-羟甲基-1,4-二氧六环-2-酮和苄氯为原料在氢化钠存在下反应制得5-苄氧甲基-1,4-二氧六环-2-酮。The above-mentioned 5-hydroxymethyl-1,4-dioxane-2-ketone can be obtained by the prior art; it can also be obtained by the following method: 5-hydroxyl-1,3-benzylidene glycerol and ethyl bromoacetate Reaction at 45-65°C in the presence of metallic sodium or sodium hydride, followed by hydrolysis twice under alkaline conditions and acidic conditions, followed by vacuum distillation to obtain 5-hydroxymethyl-1,4-dioxane-2-one, and then Using 5-hydroxymethyl-1,4-dioxane-2-one and benzyl chloride as raw materials to react in the presence of sodium hydride to prepare 5-benzyloxymethyl-1,4-dioxane-2- ketone.
5-苄氧甲基-1,4-二氧六环-2-酮分子量为222,经质谱仪(MS)测定;其结构经红外光谱(FT-IR),质子核磁共振谱(1HNMR),碳-13核磁共振谱(13CNMR)证实。The molecular weight of 5-benzyloxymethyl-1,4-dioxane-2-one is 222, determined by mass spectrometer (MS); its structure is determined by infrared spectrum (FT-IR), proton nuclear magnetic resonance spectrum ( 1 HNMR) , confirmed by carbon-13 nuclear magnetic resonance spectrum ( 13 CNMR).
采用本发明所达到的有益效果:Adopt the beneficial effect that the present invention reaches:
本发明以现有技术中的5-羟甲基-1,4-二氧六环-2-酮为原料首次设计并合成了一种结构新颖的六员环对二氧六环酮单体,即5-苄氧甲基-1,4-二氧六环-2-酮。化合物的结构经红外光谱(FT-IR),质子核磁共振谱(1HNMR),碳-13核磁共振谱(13CNMR)证实。合成的环状单体可用于开环聚合,而且通过改变环状单体上的官能团,可改变相应聚合物的物理、化学和生物学性质,并可将药物通过官能团引入单体或聚合物,从而为进一步拓展生物可降解聚对二氧六环酮及其共聚物的应用领域奠定良好的基础。The present invention uses 5-hydroxymethyl-1,4-dioxan-2-one in the prior art as a raw material for the first time to design and synthesize a six-membered ring-p-dioxanone monomer with a novel structure. That is, 5-benzyloxymethyl-1,4-dioxane-2-one. The structure of the compound was confirmed by infrared spectrum (FT-IR), proton nuclear magnetic resonance spectrum ( 1 HNMR) and carbon-13 nuclear magnetic resonance spectrum ( 13 CNMR). The synthesized cyclic monomers can be used for ring-opening polymerization, and by changing the functional groups on the cyclic monomers, the physical, chemical and biological properties of the corresponding polymers can be changed, and drugs can be introduced into monomers or polymers through functional groups, Thus laying a good foundation for further expanding the application field of biodegradable polydioxanone and its copolymer.
本发明制得的5-苄氧甲基-1,4-二氧六环-2-酮还具有以下用途:1、用于制备新型功能化生物可降解聚对二氧六环酮单体,可改善相应聚合物的物理、化学和生物学性能。2、用于制备生物可降解共聚物的单体,可与其他环状单体,如1,4-二氧六环-2-酮、丙交酯、乙交酯、ε-己内酯、三亚甲基碳酸酯以及环状磷酸酯等进行开环共聚,拓展聚对二氧六环酮的种类及其用途。通过控制共聚物中组分配比,得到可调的物理、化学和生物学性能。3、用于制备功能化环状对二氧六环酮以及聚对二氧六环酮的中间体,进一步改善聚对二氧六环酮的物理、化学和生物学性能。4、用于制备含药物或生物活性物质的环状中间体,从而制备高分子药物控释体系。The 5-benzyloxymethyl-1,4-dioxan-2-ketone prepared by the present invention also has the following purposes: 1. It is used to prepare novel functionalized biodegradable polydioxanone monomers, The physical, chemical and biological properties of the corresponding polymers can be improved. 2. The monomer used to prepare biodegradable copolymers can be combined with other cyclic monomers, such as 1,4-dioxane-2-one, lactide, glycolide, ε-caprolactone, Ring-opening copolymerization of trimethylene carbonate and cyclic phosphate, etc., to expand the types and uses of polydioxanone. Adjustable physical, chemical and biological properties can be obtained by controlling the distribution ratio of the components in the copolymer. 3. Intermediates for preparing functionalized cyclic p-dioxanone and polydioxanone, further improving the physical, chemical and biological properties of polydioxanone. 4. It is used to prepare cyclic intermediates containing drugs or biologically active substances, so as to prepare polymer drug controlled release systems.
具体实施方式Detailed ways
本发明可直接以5-羟甲基-1,4-二氧六环-2-酮和苄氯为原料反应制得5-苄氧甲基-1,4-二氧六环-2-酮。也可按下述反应式制得5-苄氧甲基-1,4-二氧六环-2-酮: The present invention can directly use 5-hydroxymethyl-1,4-dioxane-2-one and benzyl chloride as raw materials to react to prepare 5-benzyloxymethyl-1,4-dioxane-2-one . 5-benzyloxymethyl-1,4-dioxane-2-one can also be prepared according to the following reaction formula:
实施例一:Embodiment one:
5-羟基-1,3-二噁烷(化合物1)的制备:在522g苯甲醛(4.92mol)和451g甘油(4.90mol)的混合溶液中滴加催化剂量的浓硫酸,在室温下搅拌反应4h,然后用水泵对反应体系减压,并微微加热(40~45℃),以除去反应所产生的水,直至反应物变成浅黄色的清澈溶液。将其冷却至室温,搅拌1h,将500mL无水乙醚加入到反应液中,分别用10%的碳酸钠溶液(150mL×2)和150mL饱和食盐水洗涤,有机层用无水硫酸钠干燥,加入500mL无水乙醚稀释,将溶液放入冰箱,过夜,得到白色针状的晶体,用无水乙醚重结晶两次,得产物423g(产率48%),m.p.82~83℃。5-hydroxyl-1, the preparation of 3-dioxane (compound 1): in the mixed solution of 522g benzaldehyde (4.92mol) and 451g glycerol (4.90mol), the concentrated sulfuric acid of catalyst amount is added dropwise, at room temperature stirring reaction After 4 hours, the reaction system was decompressed with a water pump and heated slightly (40-45° C.) to remove the water produced by the reaction until the reactant turned into a pale yellow clear solution. It was cooled to room temperature, stirred for 1 h, 500 mL of anhydrous diethyl ether was added to the reaction solution, washed with 10% sodium carbonate solution (150 mL×2) and 150 mL of saturated brine respectively, the organic layer was dried with anhydrous sodium sulfate, and added Diluted with 500 mL of anhydrous ether, put the solution in the refrigerator overnight to obtain white needle-like crystals, recrystallized twice with anhydrous ether to obtain 423 g of the product (yield 48%), m.p.82-83°C.
实施例二:Embodiment two:
5-羟甲基-1,4-二氧六环-2-酮的制备:30g(0.167mol)化合物5-羟基-1,3-二噁烷1溶解在300mL无水甲苯中,加入3.91g(0.17mol)金属钠,在N2保护下,反应混合物微微回流,直到金属钠反应完全,将反应液冷却至室温,在搅拌下,慢慢滴加41g(0.245mol)溴乙酸乙酯。室温搅拌3h后,加入500mL甲苯稀释反应液,并倒入150mL冰水中,有机层用无水Na2SO4干燥,除去溶剂后,残余物减压蒸馏,收集190~194℃/2mmHg,得到无色油状物,放置后可以得到结晶的化合物2。将30.5g(0.115mol)化合物2溶解在200mL乙醇中,然后加入1M的NaOH的乙醇溶液200mL,室温搅拌2h。除去溶剂后,将残余物溶解在水中,并用浓盐酸酸化至pH=3。并在室温下搅拌3h后,用少量二氯甲烷洗涤反应液,以除去未反应的原料。除去水后,减压蒸馏,收集150~160℃/1mmHg的馏分,并将此馏分重蒸(b.p.128~132℃/0.07mmHg),得到无色的油状物3(5-羟甲基-1,4-二氧六环-2-酮,8.54g,产率48%)。Preparation of 5-hydroxymethyl-1,4-dioxane-2-one: 30g (0.167mol) compound 5-hydroxyl-1,3-dioxane 1 was dissolved in 300mL anhydrous toluene, and 3.91g (0.17mol) sodium metal, under the protection of N , the reaction mixture was slightly refluxed until the sodium metal reacted completely, the reaction solution was cooled to room temperature, and under stirring, slowly added dropwise 41g (0.245mol) ethyl bromoacetate. After stirring at room temperature for 3 h, add 500 mL of toluene to dilute the reaction solution and pour it into 150 mL of ice water. The organic layer is dried with anhydrous Na 2 SO 4 . Colored oil, crystallized compound 2 can be obtained after standing. Dissolve 30.5g (0.115mol) of compound 2 in 200mL of ethanol, then add 200mL of 1M NaOH in ethanol, and stir at room temperature for 2h. After removing the solvent, the residue was dissolved in water and acidified to pH=3 with concentrated hydrochloric acid. After stirring at room temperature for 3 h, the reaction solution was washed with a small amount of dichloromethane to remove unreacted raw materials. After removing water, distill under reduced pressure, collect the fraction at 150-160°C/1mmHg, and redistill this fraction (bp128-132°C/0.07mmHg) to obtain a colorless oily substance 3(5-hydroxymethyl-1, 4-dioxan-2-one, 8.54 g, 48% yield).
实施例三:Embodiment three:
5-苄氧甲基-1,4-二氧六环-2-酮的制备:将10g(0.076mol)的化合物3(5-羟甲基-1,4-二氧六环-2-酮)溶解于150mL无水1,4-二氧六环中,在此溶液中加入3.64g(0.152mol)的氢化钠和12.7g(0.1mol)氯化苄,反应混合物回流12h冷却过滤,将滤液浓缩,残留物减压蒸馏得到化合物4,7.60g(b.p.177~180℃/2mmHg),产率45%。FTIR(cm-1):1745,1378,1109,742,690;1H NMR(CDCl3,ppm):δ3.60~3.75(m,1H,-COO-CH2-CH-),3.80~3.90(m,2H,-COO-CH2-CH-),4.38(s,2H,-OCO-CH2-O-),4.40~4.50(m,2H,-CH2-O-CH2Ph),4.70(s,2H,-CH2-O-CH2Ph),7.15~7.20(m,5H,-C6H5);MS(m/z):222(M+)。The preparation of 5-benzyloxymethyl-1,4-dioxane-2-ketone: the compound 3 (5-hydroxymethyl-1,4-dioxane-2-ketone of 10g (0.076mol) ) was dissolved in 150mL of anhydrous 1,4-dioxane, 3.64g (0.152mol) of sodium hydride and 12.7g (0.1mol) of benzyl chloride were added to this solution, the reaction mixture was refluxed for 12h and cooled and filtered, and the filtrate After concentration, the residue was distilled under reduced pressure to obtain 7.60 g of compound 4 (bp 177-180° C./2 mmHg), with a yield of 45%. FTIR (cm -1 ): 1745, 1378, 1109, 742, 690; 1 H NMR (CDCl 3 , ppm): δ3.60-3.75 (m, 1H, -COO-CH 2 -CH-), 3.80-3.90 (m, 2H, -COO-CH 2 -CH-), 4.38 (s, 2H, -OCO-CH 2 -O-), 4.40~4.50 (m, 2H, -CH 2 -O-CH 2 Ph), 4.70 (s, 2H, -CH 2 -O-CH 2 Ph), 7.15-7.20 (m, 5H, -C 6 H 5 ); MS (m/z): 222 (M + ).
在上述反应中用氢氧化钠或金属钠代替氢化钠,也可得到相同产物。The same product can also be obtained by replacing sodium hydride with sodium hydroxide or metal sodium in the above reaction.
实施例四:Embodiment four:
5-苄氧甲基-1,4-二氧六环-2-酮与1,4-二氧六环-2-酮的共聚物的合成:计量的5-苄氧甲基-1,4-二氧六环-2-酮和1,4-二氧六环-2-酮以及引发剂溶液被加入到干燥的玻璃聚合管中,体系反复进行抽真空、充N2过程4次,以除去溶剂,然后在减压条件下进行封管,将其放入恒温油浴中聚合一段时间后取出,得到的聚合物用少量的三氯甲烷溶解,并用大量的甲醇沉淀,过滤,干燥至恒重。Synthesis of copolymers of 5-benzyloxymethyl-1,4-dioxan-2-one and 1,4-dioxan-2-one: metered 5-benzyloxymethyl-1,4 -dioxane-2-ketone and 1,4-dioxane-2-ketone and initiator solution are added in the dry glass polymerization tube, and the system is repeatedly evacuated and filled with N Process 4 times, with Remove the solvent, then seal the tube under reduced pressure, put it in a constant temperature oil bath to polymerize for a period of time, and take it out. The obtained polymer is dissolved with a small amount of chloroform, precipitated with a large amount of methanol, filtered, and dried to constant temperature. Heavy.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021387419A CN1156469C (en) | 2002-07-02 | 2002-07-02 | 5-benzyloxymethyl-1,4-dioxane-2-one and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021387419A CN1156469C (en) | 2002-07-02 | 2002-07-02 | 5-benzyloxymethyl-1,4-dioxane-2-one and its preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1392148A true CN1392148A (en) | 2003-01-22 |
| CN1156469C CN1156469C (en) | 2004-07-07 |
Family
ID=4749675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021387419A Expired - Fee Related CN1156469C (en) | 2002-07-02 | 2002-07-02 | 5-benzyloxymethyl-1,4-dioxane-2-one and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1156469C (en) |
-
2002
- 2002-07-02 CN CNB021387419A patent/CN1156469C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1156469C (en) | 2004-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101633654B (en) | Cyclic carbonate monomer containing acrylate functional group and its preparation and application | |
| JP3554282B2 (en) | Medical biodegradable ternary block copolymer and method for producing the same | |
| WO2010110460A1 (en) | METHOD FOR PRODUCING LACTIDE/ε-CAPROLACTONE COPOLYMER | |
| CN104672199B (en) | One kind is containing double iodine cyclic carbonate compounds and preparation method thereof | |
| CN101531756B (en) | Method for preparing water soluble polyethylene glycol/polylactic segmented polycarbonate resin | |
| CN113817153B (en) | A kind of cyano-functional carbonate monomer, cyano-functional polycarbonate and preparation method | |
| CN101538361A (en) | Cyclic esters compound polymerization catalyst, preparation method and application thereof | |
| CN101914085B (en) | 2-methacrylamiotrimethylene carbonate, preparation method and application thereof | |
| CN106496538B (en) | Synthesis method of high molecular weight polycaprolactone | |
| Peng et al. | Isoselective mechanism for asymmetric kinetic resolution polymerization of rac-lactide catalyzed by chiral tridentate bis (oxazolinylphenyl) amido ligand supported zinc complexes | |
| CN106749159B (en) | 5-Propargyloxy-trimethylene carbonate and its preparation method and application | |
| CN1156469C (en) | 5-benzyloxymethyl-1,4-dioxane-2-one and its preparation method and use | |
| CN104744426A (en) | Structure, synthesis and use of 2-ethyle-2-allyloxymethyl-1,3-propylene carbonate | |
| SG184125A1 (en) | New polyesters from asymmetrical monomers based upon bisanhydrohexitols | |
| CN101993528B (en) | Segmented copolymer and preparation method thereof | |
| CN1120164C (en) | 5-benzyloxy-trimethylene carbonate and its prepn. | |
| CN114349941B (en) | A kind of diamine-based metal catalyst and its preparation method and application | |
| CN113150254B (en) | A kind of method for preparing non-toxic polylactic acid with lactic acid aqueous solution regulation | |
| JPH02209918A (en) | Hydroxycarboxylic acid copolymer | |
| CN102757432A (en) | Synthesis of bicyclic guanidine glycolate and its catalytic ring-opening polymerization process for synthesizing degradable polymers | |
| CN101550126B (en) | ε-caprolactone derivatives and their polymers | |
| CN106543153A (en) | 2 imidazoles carbonyl, 2 methyl trimethylene carbonate and its production and use | |
| JP5256498B2 (en) | Polymer ligand, aluminum complex and method for producing polylactide | |
| CN111690142B (en) | A kind of thiopolyphosphate, its preparation method and application | |
| CN101817920B (en) | Aliphatic poly(ester-carbonate) with triple bond side group and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |